To further probe the importance of PRMT1 enzymatic activity in alternative splicing, we used PRMT1 inhibitor DB75 to treat MEG-01 cells, CMK cells and CMY cells, which all derived from AMKL leukemia patients. This evidence concerns the gene PTPN4 and acute megakaryoblastic leukemia.